3D Medicines Appoints Veteran Capital Markets Executive as New CFO

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential3D Medicines, Inc. ( (HK:1244) ) has provided an announcement. 3D Medicines Inc. has announced a leadership change in its finance function, with long-serving chief financial officer Zhang Jing resigning and experienced capital markets professional Lu Xiaohao taking over the role, effective immediately. Lu brings nearly 18 years of experience in capital operations, financial management and investment banking across domestic and international markets, including roles at PwC, Deloitte, GSK’s Greater China division, major Chinese securities firms and CFO positions at Wuhan Vickor Medical Technology and Hunan Hengchang Pharmaceutical Group, a move that may strengthen the company’s financial governance and capital markets capabilities as it pursues its strategic objectives. The most recent analyst rating on (HK:1244) stock is a Sell with a HK$4.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page. More about 3D Medicines, Inc. 3D Medicines Inc. is a Hong Kong-listed biopharmaceutical company focused on the development and commercialization of innovative medicines, operating through a group structure with subsidiaries and overseen by a board comprising executive, non-executive and independent non-executive directors. Average Trading Volume: 320,756 Technical Sentiment Signal: Buy Current Market Cap: HK$1.55B For a thorough assessment of 1244 stock, go to TipRanks’ Stock Analysis page.